Physician Views: Novartis’ Leqvio set for leg-up in Europe?

Novartis hopes to kick-start its European launch of the RNAi-based PCSK-9 inhibitor Leqvio thanks to an innovative, access collaboration with NHS England which is designed to ensure 300,000 patients are proactively treated with the therapy over the next three years.

A prior Physician Views poll we ran in November last year suggests Leqvio is a clinically compelling addition to the treatment toolbox for adults with primary hypercholesterolaemia or mixed dyslipidaemia and our latest poll seeks to ascertain if and how this view has evolved and whether physicians welcome access deals like that agreed between Novartis and the NHS.

With US approval of Leqvio now expected in early 2022, this latest poll is fielding the following questions to cardiologists based in France, Germany, Italy, Spain and the UK…

  • Do you intend to prescribe Leqvio?
  • If you anticipate prescribing Leqvio in what type of patients would you typically expect to use it?
  • Approximately what percentage of adults with primary hypercholesterolaemia or mixed dyslipidaemia under your care do you anticipate prescribing Leqvio to?
  • Novartis will work with the NHS to help proactively identify, treat and monitor eligible individuals with atherosclerotic cardiovascular disease who have experienced a cardiovascular event. Do you welcome this arrangement/would you welcome a similar arrangement in your own country?
  • Will/would this type of arrangement increase your utilisation of Leqvio?

Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here

To read more Physician Views articles, click here.